Related Experiment Videos
Activation of coagulation and disseminated intravascular coagulation in the newborn
Insights
Newborns exhibit unique coagulation "deficiencies" but can still form clots. Preterm infants may have a unique form of disseminated intravascular coagulation without low platelets.
Area of Science:
- Neonatal hemostasis
- Pediatric thrombosis
- Coagulation disorders
Background:
- Human newborns possess distinct hemostatic alterations, including reduced levels of specific coagulation factors (II, VII, IX, X, XI, XII), antithrombin III, and plasminogen.
- Despite these apparent deficiencies, newborns demonstrate the capacity to activate coagulation pathways, leading to thrombotic events.
Purpose of the Study:
- To explore the hemostatic capabilities and thrombotic potential in human newborns.
- To investigate the potential mechanisms underlying coagulation activation in neonatal populations.
- To examine specific thrombotic manifestations in preterm infants.
Main Methods:
- Review of existing literature on neonatal hemostasis and coagulation.
- Analysis of clinical evidence regarding thrombotic events in newborns.
- Comparative assessment of coagulation profiles in term versus preterm infants.
Main Results:
- Newborns exhibit reduced levels of key coagulation factors and inhibitors.
- Neonates are capable of initiating disseminated intravascular coagulation (DIC) or localized thrombotic events.
- Preterm infants may present a variant DIC characterized by the absence of thrombocytopenia.
Conclusions:
- Neonatal hemostasis is characterized by a unique profile of reduced factors and inhibitors.
- The prothrombotic potential in newborns is significant, despite apparent hemostatic deficiencies.
- Further research is needed to elucidate the precise mechanisms of coagulation activation and define the variant DIC in preterm infants.
Abstract:
Human newborns have certain hemostatic "deficiencies" which seem to be peculiar to this period of life, such as reduced factors II, VII, IX, X, XI, and XII, reduced antithrombin III levels, and reduced plasminogen levels. However, they are capable of activating the coagulation mechanism to elicit either the entity of disseminated intravascular coagulation or the occurrence of localized and diffuse thrombotic events. The mechanisms involved have yet to be defined. Evidence has been presented to suggest that preterm infants may manifest a variant form of disseminated intravascular coagulation in which thrombocytopenia is not present.